Company intelligence / Profile preview

Neurophth

Ownership: Private
Employees: ~125
Development stage: Phase 3

Overview

Neurophth has accumulated the largest sample size and longest follow-up time in investigator initiated trials (IIT) for LHON gene therapy since initiating studies in this area in China. The company positions itself as a world leader in ocular gene therapies, with ongoing clinical development and recent significant financing to support further trials.[1][2]

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

11 assets

esonadogene mvoparvovec

10 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Neurophth.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurophth.

Explore the full profile